Meeting the affordability challenges posed by orphan drugs: A survey of payers, providers, and employers
BACKGROUND: As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Payers and employers are evaluating how traditional specialty pharmacy mana...
Main Authors: | Gopalan, A. (Author), Ladikos, N. (Author), Lopata, E. (Author), Richardson, T. (Author), Terrone, C. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Academy of Managed Care Pharmacy (AMCP)
2021
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
by: Kavisha Jayasundara, et al.
Published: (2019-01-01) -
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01) -
ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION
by: M. V. Sura, et al.
Published: (2015-03-01) -
Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)